European Union Approves Gilead Sciences’ Long-Acting HIV Prevention Injection Yeytuo

Gilead Sciences has received approval from the European Union for its new HIV prevention injection, Yeytuo. Analysts and health organizations have highlighted the drug’s potential to play a significant role in reducing HIV infection rates across the region. The approval marks a key milestone for Gilead as it seeks to expand its portfolio of treatments targeting HIV.

Yeytuo is designed as a long-acting injectable medication aimed at preventing HIV transmission. Experts in the field have pointed to its potential to address gaps in existing prevention methods, particularly among populations with limited access to daily oral medications. Charities working on HIV prevention have expressed optimism about the injection’s ability to improve adherence rates and reduce barriers associated with traditional preventive measures. This development positions Yeytuo as a promising tool in ongoing efforts to combat the spread of HIV globally.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: August 26, 2025

Author

Mark Chiang